Recent blog posts
undefined European Commission gives green light to Roche's Vabysmo for treating retinal vein occlusion (RVO)
Latest Hotspot
3 min read
undefined European Commission gives green light to Roche's Vabysmo for treating retinal vein occlusion (RVO)
2 August 2024
Roche disclosed today that the European Commission has given the green light to Vabysmo® (faricimab) .
Read →
Galderma's Relfydess™ has been approved for use in Europe
Latest Hotspot
3 min read
Galderma's Relfydess™ has been approved for use in Europe
2 August 2024
Galderma has successfully completed the European decentralized procedure, leading to a favorable decision for RelfydessTM.
Read →
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
Latest Hotspot
3 min read
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
2 August 2024
Compugen has announced that the U.S. Food and Drug Administration has approved the investigational new drug application to begin a Phase 1 trial for COM503.
Read →
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer’s Disease
Latest Hotspot
4 min read
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer’s Disease
2 August 2024
Alpha Cognition has reported that the U.S. Food and Drug Administration has given the green light to ZUNVEYL® (benzgalantamine).
Read →
NewAmsterdam Pharma Reports Positive Results from BROOKLYN Phase 3 Trial on Obicetrapib in Heterozygous Familial Hypercholesterolemia
Latest Hotspot
4 min read
NewAmsterdam Pharma Reports Positive Results from BROOKLYN Phase 3 Trial on Obicetrapib in Heterozygous Familial Hypercholesterolemia
2 August 2024
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia.
Read →
European Commission Approves CStone's Sugemalimab (Cejemly®) for First-Line Non-Small Cell Lung Cancer Treatment
Latest Hotspot
4 min read
European Commission Approves CStone's Sugemalimab (Cejemly®) for First-Line Non-Small Cell Lung Cancer Treatment
2 August 2024
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer.
Read →
Nectin Therapeutics Licenses Novel Antibodies to Immunome
Latest Hotspot
2 min read
Nectin Therapeutics Licenses Novel Antibodies to Immunome
2 August 2024
According to the agreement, Immunome has obtained exclusive rights to a collection of antibodies directed at an undisclosed target.
Read →
CHMP has adopted a negative opinion on lecanemab for the EU
Latest Hotspot
3 min read
CHMP has adopted a negative opinion on lecanemab for the EU
2 August 2024
European Medicines Agency Rejects Eisai's Lecanemab for Alzheimer’s Treatment.
Read →
AbbVie Reports EU Approval of SKYRIZI® (risankizumab) for Adult Ulcerative Colitis Treatment
Latest Hotspot
3 min read
AbbVie Reports EU Approval of SKYRIZI® (risankizumab) for Adult Ulcerative Colitis Treatment
1 August 2024
AbbVie revealed that the European Commission has granted approval for SKYRIZI(risankizumab) to be used in adult patients suffering from moderately to severely active ulcerative colitis.
Read →
Chemomab Therapeutics Reveals Successful Phase 2 Study Outcomes: CM-101 Meets Key Targets
Latest Hotspot
4 min read
Chemomab Therapeutics Reveals Successful Phase 2 Study Outcomes: CM-101 Meets Key Targets
1 August 2024
Chemomab Therapeutics Announces Positive Results in Phase 2 Study: CM-101 Demonstrates Anti-Fibrotic, Anti-Inflammatory, and Anti-Cholestatic Effects in Primary Sclerosing Cholangitis.
Read →
FDA Approves BioMarin's BRINEURA® for CLN2 Disease in Children Under 3
Latest Hotspot
3 min read
FDA Approves BioMarin's BRINEURA® for CLN2 Disease in Children Under 3
1 August 2024
The FDA has approved BioMarin's BRINEURA® (cerliponase alfa) for treating children under 3 years old with CLN2 disease.
Read →
IASO Bio Gets NMPA Nod for IASO-782 IND in SLE Treatment
Latest Hotspot
3 min read
IASO Bio Gets NMPA Nod for IASO-782 IND in SLE Treatment
31 July 2024
IASO Bio Receives NMPA Clearance for IASO-782 IND Application to Address Systemic Lupus Erythematosus (SLE).
Read →